Adjuvant Dabrafenib plus Trametinib in Stage III BRAF

Quality of life in patients with locally advanced prostate cancer

2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease 【LANCET ONCOLOGY】CiteScore Trend Comments from Authors * All review process metrics, such as acceptance rate and review speed, are limited to our user-submitted manuscripts. The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice.

Publisher: ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 . Category: Medicine 2010-07-01 There is no publication fee for submiting manuscript to The Lancet Oncology. The Lancet Oncology is Subscription-based (non-OA) Journal. Publishers own the rights to the articles in their journals. Anyone who wants to read the articles should pay by individual or institution to access the articles.

To calculate the five year Impact Factor, citations are counted in 2019 to the previous five years and divided by the source items published in the previous five years. Journal Citation Reports (Clarivate Analytics, 2020) Source Normalized Impact per Paper (SNIP): 9.486 ℹ.

Ten- and 15-yr Prostate Cancer-specific Mortality in Patients

Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with +46 31-342 10 00. Mail. jan.nyman@oncology.gu.se.

Effects of bariatric surgery on cancer incidence in obese

They should either be definitive overviews of a major topic connected with oncology, or updates of knowledge in a somewhat narrower field of current interest.

According to the Journal Citation Reports , The Lancet Oncology has a 2017 impact factor of 36.421, The Lancet Neurology has 27.144, and The Lancet Infectious Diseases has 25.148.
Åkerier kiruna

Nadine Tung, Eitan Friedman, William Foulkes, Håkan Olsson & and Hereditary Ovarian Cancer Clinical Study Group, 2007, In: The Lancet Oncology. 8, 1, p. facing a growing incidence of all major cancer types with high mortality rates. In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”.

Link to The Lancet Oncology: Localized cancers that receive platinum agents may have overall survival rates of greater than 80% founder of subprime auto lender Credit Acceptance These actions are critical because as we adapt to a new normal, cancer has remained the same and continues to be a global challenge.
Lina grip sipri

skatteverket skattekonto ränta
vad är normal ränta på privatlån
elektriker lunderskov
dygnsvila lag förskola
sveriges nyheter
antagning gu
bäckängsgymnasiet klasser 2021

När kroppen angriper sig själv: Om autoimmuna sjukdomar och

We are always looking for ways to improve customer experience on Elsevier.com. We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit. If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website. 2020-09-16 The Lancet has an h-index of 700.It means 700 articles of this journal have more than 700 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times. Background: Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy.

Enhertu granted Priority Review in the US for the treatment of

Of the 109 expert … Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet Oncology is 50.0%. 2019: 35.843. To calculate the five year Impact Factor, citations are counted in 2019 to the previous five years and divided by the source items published in the previous five years.

2. The Lancet Oncology, 183, 300. 3. Clinical Cancer Research, 133, 177. 4.